“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology (Prevalence of Type 1 and 2 Diabetes) in the US market along with the associated economic burden and productivity loss.
Diabetes rates in the US have been increasing substantially. While the number of people with diabetes in the US continues to grow, the number of new cases has been declining since 2009, after decades of increases in new cases. Although the numbers are not growing dramatically each year, they are still alarmingly high. About 8.1 Million people with diabetes do not have knowledge that they have diabetes as prediabetes and type2 diabetes have few physical symptoms.
Diabetes mellitus being the most common chronic disease with high mortality, morbidity and costs, the number of people with diabetes is still increasing in US and other countries. More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes. Though the benefits of tight control of blood glucose have been well recognized still the management of diabetes is complex which demands for the more efficient standardized antidiabetic regimen.
US insulin market occupies more than 70% of the overall insulin market and is expected to grow significantly until 2022 owing to the growing number of individuals with diabetes. Factors such as better accessibility to treatment therapies and favorable reimbursement programs will result in the high turnout of patients opting for diabetes treatment, which in turn will boost the market’s growth prospects in this region.
The US Antidiabetics Drug Market has seen a resurgence of activity in recent years with promising new products, such as ultra-rapid-acting and liver targeted insulin analogues, and insulin plus GLP-1 combinations in late stage development. Earlier stage candidates include several oral formulations, as well as ultra-long acting insulin analogues. Some ultra-long acting insulin analogues in development have the potential to greatly reduce the dosing frequency to just once weekly for basal insulin needs, as opposed to once daily.
In addition, the prospect of promising drugs in the pipeline, along with increasing awareness, is expected to contribute to the market's growth during the forecast period. The market is dominated by three key players: Eli Lilly, Novo Nordisk, and Sanofi. Novo Nordisk is the major vendor in the global insulin market. The largest product wise market revenue was generated by Lantus, which is marketed by Sanofi.
“US Antidiabetics Drug Market Outlook 2022” report highlights:
US Diabetes Epidemiology
US Antidiabetics Market Overview
Key Marketed Antidiabetic Drugs in US
US Biosimilar Insulin Market
US Antidiabetics Drug Market Future Prospects
Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication
Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus
Cataloguing of Antidiabetic Agents
4.1 Antidiabetic: Oral Agents
4.1.2 Thiazolidinediones (TZDs)
4.1.5 andalpha;- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2
Antidiabetic: Injectable Drugs
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus
US Diabetes Epidemiology
6.1 Prevalence of Type 1 and 2 Diabetes
6.2 Economic Burden Associated with Type 1 and 2 Diabetes: Productivity Loss and Medical Bills
Figure 9-1: Comparison of Price of Insulin Lantus and Basaglar
Figure 10-2: Estimated Insulin Basaglar Sales in Diabetes
Figure 10-1: Major Accelerative Parameters for Antidiabetic Market in US
Figure 10-2: Estimated Impact of Increasing Trend in Obesity by 2020
Figure 10-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
Figure 10-4: Major challenges in Antidiabetics Market
Figure 10-5: Important Challenges with the Use of Insulin
Figure 11-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2022
Figure 11-2: Illustration of Antidiabetic Drugs Under Development
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.